GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: RMD
Underweight $52

Resmed Inc. (NYSE: RMD) rated to Underweight with price target $52 by Barclays

Tuesday,  Jan 19, 2016  1:25 PM ET by Kristen Bailey

Barclays rated Resmed Inc. (NYSE:
RMD) to Underweight with price target $52 with today's price of $53.24.

ResMed Inc. is a holding company. Through its subsidiaries, the Company develops, manufactures and distributes medical equipment for treating, diagnosing and managing sleep-disordered breathing (SDB) and other respiratory disorders, including obstructive sleep apnea (OSA). It has developed nasal continuous positive airway pressure (CPAP) as a non-invasive treatment for OSA. CPAP systems deliver pressurized air, typically through a nasal mask, to prevent collapse of the upper airway during sleep. The Company has developed a number of products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. ResMed Inc. sells its products in over 70 countries through a combination of wholly owned subsidiaries and independent distributors to sleep clinics, home healthcare dealers and third-party payers. On April 30, 2009, it acquired Respicure Medsys PVT.LTD. In October 2009, ResMed Inc. acquired Laboratoires Narval.

Barclays



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy